Literature DB >> 28801207

CredibleMeds.org: What does it offer?

Raymond L Woosley1, Kristin Black2, C William Heise3, Klaus Romero4.   

Abstract

Since the 1990s, when numerous non-cardiac drugs were first recognized to have the potential to prolong the QT interval and cause torsades de pointes (TdP), clinicians, drug regulators, drug developers, and clinical investigators have become aware of the complexities of assessing evidence and determining TdP causality for the many drugs being marketed or under development. To facilitate better understanding, the Arizona Center for Education and Research on Therapeutics, known as AZCERT, has developed the CredibleMeds.org website which includes QTdrugs, a listing of over 220 drugs placed in four risk categories based on their association with QT prolongation and TdP. Since the site was launched in 1999, it has become the single and most reliable source of information of its kind for patients, healthcare providers, and research scientists. Over 96,000 registered users rely on the QTdrugs database as their primary resource to inform their medication use, their prescribing or their clinical research into the impact of QT-prolonging drugs and drug-induced arrhythmias. The QTdrugs lists are increasingly used as the basis for clinical decision support systems in healthcare and for metrics of prescribing quality by healthcare insurers. A free smartphone app and an application program interface enable rapid and mobile access to the lists. Also, the CredibleMeds website offers numerous educational resources for patients, educators and healthcare providers that foster the safe use of medications.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Arrhythmia; QT interval; QT prolongation; Sudden death; Torsades de pointes

Mesh:

Year:  2017        PMID: 28801207     DOI: 10.1016/j.tcm.2017.07.010

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  21 in total

Review 1.  QT Prolongation and Malignant Arrhythmia: How Serious a Problem?

Authors:  Christos-Konstantinos Antoniou; Polychronis Dilaveris; Panagiota Manolakou; Spyridon Galanakos; Nikolaos Magkas; Konstantinos Gatzoulis; Dimitrios Tousoulis
Journal:  Eur Cardiol       Date:  2017-12

2.  QT interval prolongation and Torsades de Pointes with donepezil, rivastigmine and galantamine.

Authors:  Katie Malone; Jules C Hancox
Journal:  Ther Adv Drug Saf       Date:  2020-08-17

3.  QTc Interval-Prolonging Medications Among Patients With Lung Cancer: Implications for Clinical Trial Eligibility and Clinical Care.

Authors:  Tri Le; Hui Yang; Sawsan Rashdan; Mark S Link; Vlad G Zaha; Carlos Alvarez; David E Gerber
Journal:  Clin Lung Cancer       Date:  2019-11-25       Impact factor: 4.785

Review 4.  [Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic].

Authors:  H Javelot; P-M Llorca; D Drapier; E Fakra; C Hingray; G Meyer; S Dizet; A Egron; C Straczek; M Roser; M Masson; R Gaillard; P Fossati; E Haffen
Journal:  Encephale       Date:  2020-05-04       Impact factor: 1.291

Review 5.  Withdrawal of prenylamine: perspectives on pharmacological, clinical and regulatory outcomes following the first QT-related casualty.

Authors:  Rashmi R Shah; Peter D Stonier
Journal:  Ther Adv Drug Saf       Date:  2018-06-18

6.  Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug development.

Authors:  Sebastian Polak; Klaus Romero; Alexander Berg; Nikunjkumar Patel; Masoud Jamei; David Hermann; Debra Hanna
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-03-08       Impact factor: 2.745

7.  High prevalence of ventricular repolarization abnormalities in people carrying TGFβR2 mutations.

Authors:  F Extramiana; O Milleron; S Elbitar; A Uccellini; M Langeois; M Spentchian; G Delorme; F Arnoult; I Denjoy; C Bouleti; V Fressart; F Iserin; P Maison-Blanche; M Abifadel; A Leenhardt; C Boileau; G Jondeau
Journal:  Sci Rep       Date:  2018-08-29       Impact factor: 4.379

8.  Development of a Human iPSC Cardiomyocyte-Based Scoring System for Cardiac Hazard Identification in Early Drug Safety De-risking.

Authors:  Ivan Kopljar; Hua Rong Lu; Karel Van Ammel; Martin Otava; Fetene Tekle; Ard Teisman; David J Gallacher
Journal:  Stem Cell Reports       Date:  2018-12-11       Impact factor: 7.765

9.  Association between Use of Methadone, Other Central Nervous System Depressants, and QTc Interval-Prolonging Medications and Risk of Mortality in a Large Cohort of Women Living with or at Risk for Human Immunodeficiency Virus Infection.

Authors:  Bani Tamraz; Lori Reisner; Audrey L French; Samuel T King; Margaret A Fischl; Igho Ofotokun; Angela Kashuba; Joel Milam; Kerry Murphy; Michael Augenbraun; Chenglong Liu; Patrick R Finley; Bradley Aouizerat; Jennifer Cocohoba; Stephen Gange; Peter Bacchetti; Ruth M Greenblatt
Journal:  Pharmacotherapy       Date:  2019-08-13       Impact factor: 4.705

10.  Prediction of Drug-Induced Long QT Syndrome Using Machine Learning Applied to Harmonized Electronic Health Record Data.

Authors:  Steven T Simon; Divneet Mandair; Premanand Tiwari; Michael A Rosenberg
Journal:  J Cardiovasc Pharmacol Ther       Date:  2021-03-08       Impact factor: 2.457

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.